Azathioprine treatment and thiopurine metabolism in rheumatic diseases. Introduction and first results of investigation.
Stolk
J N
JN
Department of Rheumatology, University Hospital Nijmegen, The Netherlands.
Boerbooms
A M
AM
De Abreu
R A
RA
van de Putte
L B
LB
D015720:5'-Nucleotidase / Q000097:blood; D018501:Antirheumatic Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D001379:Azathioprine / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D006801:Humans; D007041:Hypoxanthine Phosphoribosyltransferase / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D015122:Mercaptopurine / Q000097:blood*; D008780:Methyltransferases / Q000097:blood; D012016:Reference Values; D012217:Rheumatoid Factor / Q000097:blood
D018501:Antirheumatic Agents; D007075:Immunoglobulin M; D012217:Rheumatoid Factor; D015122:Mercaptopurine; D008780:Methyltransferases; C022745:thiopurine methyltransferase; D007041:Hypoxanthine Phosphoribosyltransferase; D015720:5'-Nucleotidase; D001379:Azathioprine